Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462191 | 0.79 | EPHX1 (0.56) | EPHX1ALOX15ZDHHC20ZDHHC2 | |
| SCHEMBL1442907 | 0.79 | HDAC3 (0.49) | HDAC1HDAC11HDAC8HDAC6HDAC3 | |
| SCHEMBL8931322 | 0.78 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL3278553 | 0.78 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL3278820 | 0.78 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL3277865 | 0.78 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL28199266 | 0.78 | EPHX1 (0.59) | EPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL13731861 | 0.77 | EPHX1 (0.52) | HDAC1HDAC11HDAC8HDAC6HDAC3 | |
| SCHEMBL2420545 | 0.77 | EPHX1 (0.52) | HDAC1HDAC11HDAC8HDAC6HDAC3 | |
| SCHEMBL21122034 | 0.77 | EPHX1 (0.52) | HDAC1HDAC11HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247577-B2 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-2247577-B1 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-8629288-B2 | Method for the regioselective synthesis of 1-alky1-3-haloalkyl-pyrazole-4-carboxylic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8592605-B2 | Method for the regioselective synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130197239-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-Haloalkyl-Pyrazole-4-Carboxylic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2247577-A2 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL PYROAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| EP-2133341-A1 | Method for regioselective synthesis of 1-alkyl-3-haloalkyl-1-pyrazol-4-carbonic acid derivatives | Bayer CropScience AG (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009106230-A2 | METHOD FOR THE REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL–PYROAZOLE-4-CARBOXYLIC ACID DERIVATIVES | BAYER CROPSCIENCE AKTENGESELLSCHAFT (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009642-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-haloalkyl-pyrazole-4-carboxylic Acid Derivatives | ATL3, HCAR3, AADAC | HDAC1 430/4885HDAC11 319/4885HDAC8 1550/4885 |
| US-20130197239-A1 | Method for the Regioselective Synthesis of 1-Alkyl-3-Haloalkyl-Pyrazole-4-Carboxylic Acid Derivatives | ATL3, HCAR3, AADAC | HDAC1 430/4885HDAC11 319/4885HDAC8 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.